
Ohio's Medicaid Rulebook Bars GLP-1s for Obesity; An AHA Abstract Pits GLP-1s Against Metformin in Prediabetes; Australia Clears the Wegovy Pill — November 03, 2026
Shownotes
An advocacy group is pushing Ohio to rewrite the rule that keeps its Medicaid program from covering GLP-1s for adult obesity, while a large, preliminary health-records study for the American Heart Association links GLP-1s to better prediabetes outcomes than metformin. Australia's drug regulator has also approved the Wegovy pill.
In this episode- Group seeks Ohio Medicaid coverage for GLP-1 weight-loss drugs — Daytondailynews“The Ohio Department of Medicaid is prohibited from covering GLP-1 medications specifically for the condition of obesity in adults due to a restriction in the Ohio administrative code, but a national organization is advocating for state officials to change this.”
- GLP-1 meds linked to lower diabetes, heart risks than standard diabetes prevention med | American Heart Association — American Heart Association“GLP-1 (glucagon-like peptide-1 receptor agonists) medications, currently popular for weight-loss, may help prevent Type 2 diabetes and lower the risk of heart attack and stroke more than the standard diabetes prevention medication metformin among people with prediabetes,…”
- Watchdog’s huge call on weight-loss drug pill - Yahoo News Australia — Emma Kirk“A Department of Health spokesman said the TGA approved the registration of a Wegovy oral tablet in 1.5mg, 4mg, 9mg and 25mg strengths.”
Daily TopFive for GLP-1 Daily: Ozempic & Wegovy News. Links above go to the original articles. Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email [email protected].
Kapitel
Kapitel werden geladen …